Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 36, Issue 1, 2013, Pages 63-69

  Konnai, Satoru ^a   Suzuki, Saori ^a   Shirai, Tatsuya ^a   Ikebuchi, Ryoyo ^a   Okagawa, Tomohiro ^a   Sunden, Yuji ^a   Mingala, Claro N ^b   Onuma, Misao ^a   Murata, Shiro ^a   Ohashi, Kazuhiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Philippine Carabao Center National Headquarters and Genepool   (Philippines)

Author keywords

BLV; IFN ; IL 2; LAG 3; MHC class II; PD 1; PD L1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BOVINE LEUKEMIA VIRUS; CATTLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; LYMPHOCYTE COUNT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROVIRUS INFECTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD274; CATTLE; ENZOOTIC BOVINE LEUKOSIS; LEUKEMIA VIRUS, BOVINE; LYMPHOCYTE SUBSETS; LYMPHOCYTOSIS; T-LYMPHOCYTES;

ANIMALIA; BOS; BOVINAE; BOVINE LEUKEMIA VIRUS;

EID: 84871037722     PISSN: 01479571     EISSN: 18781667     Source Type: Journal    
DOI: 10.1016/j.cimid.2012.09.005     Document Type: Article

References (41)

1. Triebel F., Jitsukawa S., Baixeras E., Roman-Roman S., Genevee C., Viegas-Pequignot E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. Journal of Experimental Medicine 1990, 171:1393-1405.
2. Camisaschi C., Casati C., Rini F., Perego M., De Filippo A., Triebel F., et al. LAG-3 expression defines a subset of CD4+CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. Journal of Immunology 2010, 184:6545-6551.
3. Workman C.J., Wang Y., El Kasmi K.C., Pardoll D.M., Murray P.J., Drake C.G., et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. Journal of Immunology 2009, 182:1885-1891.
4. Workman C.J., Dugger K.J., Vignali D.A. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. Journal of Immunology 2002, 169:5392-5395.
5. Huard B., Prigent P., Tournier M., Bruniquel D., Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. European Journal of Immunology 1995, 25:2718-2721.
6. Workman C.J., Vignali D.A. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. European Journal of Cancer 2003, 33:970-979.
7. Workman C.J., Cauley L.S., Kim I.J., Blackman M.A., Woodland D.L., Vignali D.A. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. Journal of Immunology 2004, 172:5450-5455.
8. Blank C., Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunology, Immunotherapy 2007, 56:739-745.
9. Keir M.E., Butte M.E., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008, 26:677-704.
10. Khaitan A., Unutmaz D. Revisiting immune exhaustion during HIV infection. Current HIV/AIDS Report 2011, 8:4-11.
11. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology 2009, 10:29-37.
12. + T-cell function in Hodgkin lymphoma patients. Blood 2006, 108:2280-2289.
13. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:7875-7880.
14. + T cell accumulation and effector function in murine self- and tumor-tolerance systems. Journal of Clinical Investigation 2007, 117:3383-3392.
15. Flies D.B., Sandler B.J., Sznol M., Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale Journal of Biology and Medicine 2011, 84:409-421.
16. Porichis F., Kaufmann D.E. Role of PD-1 in HIV pathogenesis and as target for therapy. Current HIV/AIDS Report 2012, 9:81-90.
17. Shirai T., Konnai S., Ikebuchi R., Okagawa T., Suzuki S., Sunden Y., et al. Molecular cloning of bovine lymphocyte activation gene-3 and its expression characteristics in bovine leukemia virus-infected cattle. Veterinary Immunology and Immunopathology 2011, 144:462-467.
18. Ikebuchi R., Konnai S., Sunden Y., Onuma M., Ohashi K. Molecular cloning and expression analysis of bovine programmed death-1. Microbiology and Immunology 2010, 54:291-298.
19. Ikebuchi R., Konnai S., Shirai T., Sunden Y., Murata S., Onuma M., et al. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. Veterinary Research 2011, 42:103.
20. Konnai S., Usui T., Ikeda M., Kohara J., Hirata T., Okada K., et al. Imbalance of tumor necrosis factor receptors during progression in bovine leukemia virus infection. Virology 2005, 339:239-248.
21. Miyasaka M., Trnka Z. Sheep as an experimental model for immunology: immunological techniques in vitro and in vivo. Immunological methods 1985, vol. 3:403-422. Academic Press, Inc., New York.
22. Konnai S., Usui T., Ohashi K., Onuma M. The rapid quantitative analysis of bovine cytokine genes by real-time RT-PCR. Veterinary Microbiology 2003, 94:283-294.
23. Schwartz I., Levy D. Pathobiology of bovine leukemia virus. Veterinary Research 1994, 25:521-536.
24. + T cells in response to gag- and env-encoded BLV proteins. Journal of Virology 1996, 70:7584-7593.
25. Pyeon D., O'Reilly K.L., Splitter G.A. Increased interleukin-10 mRNA expression in tumor-bearing or persistently lymphocytotic animals infected with bovine leukemia virus. Journal of Virology 1996, 70:5706-5710.
26. Pyeon D., Splitter G.A. Interleukin-12 p40 mRNA expression in bovine leukemia virus-infected animals: increase in alymphocytosis but decrease in persistent lymphocytosis. Journal of Virology 1998, 72:6917-6921.
27. Stone D.M., Hof A.J., Davis W.C. Up-regulation of IL-2 receptor alpha and MHC class II expression on lymphocyte subpopulations from bovine leukemia virus infected lymphocytotic cows. Veterinary Immunology and Immunopathology 1995, 48:65-76.
28. Annunziato F., Manetti R., Tomasévic I., Guidizi M.G., Biagiotti R., Giannò V., et al. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB Journal 1996, 10:769-776.
29. Annunziato F., Manetti R., Cosmi L., Galli G., Heusser C.H., Romagnani S., et al. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. European Journal of Immunology 1997, 27:2239-2244.
30. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
31. Finnefrock A.C., Tang A., Li F., Freed C., Feng M., Cox K.S., et al. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. Journal of Immunology 2010, 182:980-987.
32. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
33. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology 2012, 24:207-212.
34. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research 2008, 14:3044-3051.
35. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010, 28:3167-3175.
36. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research 2012, 72:917-927.
37. Butler N.S., Moebius J., Pewe L.L., Traore B., Doumbo O.K., Tygrett L.T., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nature Immunology 2011, 13:188-195.
38. + patients developing immune reconstitution inflammatory syndrome. Blood 2010, 116:3818-3827.
39. Brenner J., Van-Haam M., Savir D., Trainin Z. The implication of BLV infection in the productivity, reproductive capacity and survival rate of a dairy cow. Veterinary Immunology and Immunopathology 1989, 22:299-305.
40. Erskine R.J., Bartlett P.C., Byrem T.M., Render C.L., Febvay C., Houseman J.T. Association between bovine leukemia virus, production, and population age in Michigan dairy herds. Journal of Dairy Science 2012, 95:727-734.
41. Ott S.L., Johnson R., Wells S.J. Association between bovine-leukosis virus seroprevalence and herd-level productivity on US dairy farms. Preventive Veterinary Medicine 2003, 61:249-262.